Studies of the renal vasoactive systems in hyporeninemic hypoaldosteronism. 1981

J A Hahn, and R D Zipser, and A Barg, and R A Stone, and P K Zia, and W A Hsueh, and R Horton

Plasma renin activity, total renin, active renin, and aldosterone were measured as well as urinary prostaglandin E2 and kallikrein in a group of patients with hyperkalemia (6.1-7.7 mEq per liter) and hyporeninemic hypoaldosteronism. Plasma renin activity and aldosterone were low and the response was markedly blunted to upright posture, and furosemide. The rise in cortisol but not aldosterone was normal following ACTH stimulation. Active renin was depressed; however, total renin was normal. Urine PGE was variable including some low values, but the mean of the group was normal (p greater than 0.1). Urine kallikrein excretion was markedly diminished and undetectable in most cases. Fludrocortisone normalized potassium but minimally increased kallikrein in the patients. The possibility exists that kallikrein deficiency in these patients may underlie the inability to generate active renin.

UI MeSH Term Description Entries
D007610 Kallikreins Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC 3.4.21.34), TISSUE KALLIKREIN (EC 3.4.21.35), and PROSTATE-SPECIFIC ANTIGEN (EC 3.4.21.77). Kallikrein,Kininogenase,Callicrein,Dilminal,Kallidinogenase,Kalliginogenase,Kallikrein A,Kallikrein B',Kallikrein Light Chain,Kinin-Forming Enzyme,Padutin,alpha-Kallikrein,beta-Kallikrein,beta-Kallikrein B,Enzyme, Kinin-Forming,Kinin Forming Enzyme,Light Chain, Kallikrein,alpha Kallikrein,beta Kallikrein,beta Kallikrein B
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011187 Posture The position or physical attitude of the body. Postures
D011458 Prostaglandins E (11 alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid (PGE(1)); (5Z,11 alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid (PGE(2)); and (5Z,11 alpha,13E,15S,17Z)-11,15-dihydroxy-9-oxoprosta-5,13,17-trien-1-oic acid (PGE(3)). Three of the six naturally occurring prostaglandins. They are considered primary in that no one is derived from another in living organisms. Originally isolated from sheep seminal fluid and vesicles, they are found in many organs and tissues and play a major role in mediating various physiological activities. PGE
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D005260 Female Females
D005438 Fludrocortisone A synthetic mineralocorticoid with anti-inflammatory activity. 9-Fluorocortisol,9 alpha Fludrohydrocortisone,9 alpha-Fluoro-17-Hydroxycorticosterone,9 alpha-Fluorohydrocortisone,9-Fluoro-17-Hydroxycortisone,9-Fluorohydrocortisone,Astonin,Astonin Merck,Astonin-H,FCOL,9 Fluoro 17 Hydroxycortisone,9 Fluorocortisol,9 Fluorohydrocortisone,9 alpha Fluoro 17 Hydroxycorticosterone,9 alpha Fluorohydrocortisone,Astonin H,Merck, Astonin
D005665 Furosemide A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY. Frusemide,Fursemide,Errolon,Frusemid,Furanthril,Furantral,Furosemide Monohydrochloride,Furosemide Monosodium Salt,Fusid,Lasix
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J A Hahn, and R D Zipser, and A Barg, and R A Stone, and P K Zia, and W A Hsueh, and R Horton
January 1982, Medicina,
J A Hahn, and R D Zipser, and A Barg, and R A Stone, and P K Zia, and W A Hsueh, and R Horton
March 1977, Southern medical journal,
J A Hahn, and R D Zipser, and A Barg, and R A Stone, and P K Zia, and W A Hsueh, and R Horton
January 1997, Ryoikibetsu shokogun shirizu,
J A Hahn, and R D Zipser, and A Barg, and R A Stone, and P K Zia, and W A Hsueh, and R Horton
April 1986, The New England journal of medicine,
J A Hahn, and R D Zipser, and A Barg, and R A Stone, and P K Zia, and W A Hsueh, and R Horton
March 1981, Medicina clinica,
J A Hahn, and R D Zipser, and A Barg, and R A Stone, and P K Zia, and W A Hsueh, and R Horton
January 1981, Vutreshni bolesti,
J A Hahn, and R D Zipser, and A Barg, and R A Stone, and P K Zia, and W A Hsueh, and R Horton
February 1988, Medicina clinica,
J A Hahn, and R D Zipser, and A Barg, and R A Stone, and P K Zia, and W A Hsueh, and R Horton
December 2001, Nihon rinsho. Japanese journal of clinical medicine,
J A Hahn, and R D Zipser, and A Barg, and R A Stone, and P K Zia, and W A Hsueh, and R Horton
January 1979, Advances in internal medicine,
J A Hahn, and R D Zipser, and A Barg, and R A Stone, and P K Zia, and W A Hsueh, and R Horton
June 1975, Metabolism: clinical and experimental,
Copied contents to your clipboard!